MBNL1 and myotonic dystrophy type 1: Repeated systemic injections of Pip6a-PMO at 12.5 mg/kg led to the complete correction of Cncl1 and Mbnl1 DM1 alternative splicing while heatmap results demonstrate a global gene expression correction in treated mice [35].